Advances of mRNA vaccine in tumor: a maze of opportunities and challenges DOI Creative Commons
Yuan Yuan, Fan Gao, Ying Chang

et al.

Biomarker Research, Journal Year: 2023, Volume and Issue: 11(1)

Published: Jan. 18, 2023

Abstract High-frequency mutations in tumor genomes could be exploited as an asset for developing vaccines. In recent years, with the tremendous breakthrough genomics, intelligence algorithm, and in-depth insight of immunology, it has become possible to rapidly target genomic alterations cell rationally select vaccine targets. Among a variety candidate platforms, early application mRNA was limited by instability low efficiency excessive immunogenicity until successful development vaccines against SARS-COV-2 broken technical bottleneck preparation, allowing prepared economical way good performance stability efficiency. this review, we systematically summarized classification characteristics antigens, general process methods screening neoantigens, strategies preparations advances clinical trials, well presented main challenges current development.

Language: Английский

Cancer vaccines as promising immuno-therapeutics: platforms and current progress DOI Creative Commons
Jian Liu,

Minyang Fu,

Manni Wang

et al.

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: March 18, 2022

Abstract Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy of solid tumors. Cancer stimulates anti-tumor immunity antigens, which could be delivered form whole cells, peptides, nucleic acids, etc . Ideal vaccines overcome immune suppression tumors and induce both humoral cellular immunity. In this review, we introduced working mechanism summarized four platforms for development. We also highlighted research vaccines, especially focusing their application efficacy, might hopefully facilitate future design vaccine.

Language: Английский

Citations

495

Neoantigens: promising targets for cancer therapy DOI Creative Commons
Na Xie, Guobo Shen, Wei Gao

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Jan. 6, 2023

Abstract Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy antibody-based therapies, especially for solid tumors. Neoantigens are newly formed antigens generated by cells as a result various tumor-specific alterations, such genomic mutation, dysregulated RNA splicing, disordered post-translational modification, integrated viral open reading frames. recognized non-self trigger an immune response that is not subject to central peripheral tolerance. The quick identification prediction neoantigens been made possible advanced next-generation sequencing bioinformatic technologies. Compared tumor-associated antigens, highly immunogenic provide emerging targets personalized serve prospective predictors survival prognosis checkpoint blockade responses. therapies will be aided understanding mechanism underlying neoantigen-induced anti-tumor streamlining process neoantigen-based immunotherapies. This review provides overview on characterization outlines clinical applications immunotherapeutic strategies based neoantigens. We also explore their current status, inherent challenges, translation potential.

Language: Английский

Citations

476

Dynamics and specificities of T cells in cancer immunotherapy DOI
Giacomo Oliveira, Catherine J. Wu

Nature reviews. Cancer, Journal Year: 2023, Volume and Issue: 23(5), P. 295 - 316

Published: April 12, 2023

Language: Английский

Citations

250

mRNA-based cancer therapeutics DOI
Chuang LIU,

Qiangqiang Shi,

Xiangang Huang

et al.

Nature reviews. Cancer, Journal Year: 2023, Volume and Issue: 23(8), P. 526 - 543

Published: June 13, 2023

Language: Английский

Citations

226

Therapeutic cancer vaccines: advancements, challenges and prospects DOI Creative Commons
Ting Fan, Mingna Zhang, Jingxian Yang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Dec. 13, 2023

With the development and regulatory approval of immune checkpoint inhibitors adoptive cell therapies, cancer immunotherapy has undergone a profound transformation over past decades. Recently, therapeutic vaccines have shown promise by eliciting de novo T responses targeting tumor antigens, including tumor-associated antigens tumor-specific antigens. The objective was to amplify diversify intrinsic repertoire cells. However, complete realization these capabilities remains an ongoing pursuit. Therefore, we provide overview current landscape in this review. range antigen selection, delivery systems strategic nuances underlying effective presentation pioneered vaccine design. Furthermore, review addresses status clinical trials discusses their strategies, focusing on immunogenicity anti-tumor efficacy assessment. attempts toward developing not yielded breakthrough outcomes due significant challenges, microenvironment suppression, optimal candidate identification, response evaluation, manufacturing acceleration. field is poised overcome hurdles improve patient future acknowledging complexities persistently striving surmount inherent constraints.

Language: Английский

Citations

211

Trends in the approval of cancer therapies by the FDA in the twenty-first century DOI
Emma C. Scott, Andrea Baines,

Yutao Gong

et al.

Nature Reviews Drug Discovery, Journal Year: 2023, Volume and Issue: 22(8), P. 625 - 640

Published: June 21, 2023

Language: Английский

Citations

159

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy DOI
Cristina Puig-Saus,

Barbara Sennino,

Songming Peng

et al.

Nature, Journal Year: 2023, Volume and Issue: 615(7953), P. 697 - 704

Published: March 8, 2023

Language: Английский

Citations

103

Immunology and immunotherapy of cholangiocarcinoma DOI
Tim F. Greten, Robert F. Schwabe,

Nabeel Bardeesy

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(6), P. 349 - 365

Published: Jan. 25, 2023

Language: Английский

Citations

91

Recent Advances and Challenges in Cancer Immunotherapy DOI Open Access

Chelsea Peterson,

Nathan Denlinger, Yiping Yang

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(16), P. 3972 - 3972

Published: Aug. 17, 2022

Cancer immunotherapy has revolutionized the field of oncology in recent years. Harnessing immune system to treat cancer led a large growth number novel immunotherapeutic strategies, including checkpoint inhibition, chimeric antigen receptor T-cell therapy and vaccination. In this review, we will discuss current landscape immuno-oncology research, with focus on elements that influence outcomes. We also highlight advances basic aspects tumor immunology, particular, role immunosuppressive cells within microenvironment regulating antitumor immunity. Lastly, how understanding immunology can lead development new strategies.

Language: Английский

Citations

82

Biomimetic and bioinspired nano‐platforms for cancer vaccine development DOI Creative Commons

Chenchao Feng,

Peng Tan, Guangjun Nie

et al.

Exploration, Journal Year: 2023, Volume and Issue: 3(3)

Published: April 25, 2023

The advent of immunotherapy has revolutionized the treating modalities cancer. Cancer vaccine, aiming to harness host immune system induce a tumor-specific killing effect, holds great promises for its broad patient coverage, high safety, and combination potentials. Despite promising, clinical translation cancer vaccines faces obstacles including lack potency, limited options tumor antigens adjuvants, immunosuppressive microenvironment. Biomimetic bioinspired nanotechnology provides new impetus designing concepts vaccines. Through mimicking stealth coating, pathogen recognition pattern, tissue tropism pathogen, other irreplaceable properties from nature, biomimetic could gain functions such as longstanding, targeting, self-adjuvanting, on-demand cargo release. specific behavior endogenous molecules each type living entity (cell or microorganism) offer unique features address needs immunotherapy. In this review, strategies inspired by eukaryotic cells, bacteria, viruses will be overviewed advancing vaccine development. Our insights into future development shared at end expediting translation.

Language: Английский

Citations

80